



OppenheimerFunds®

The Right Way
to Invest

6 October 2017

The Bombay Stock Exchange Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street, Fort,
Mumbai 400 001
India
Tel No : (022) 22721233/4
Email: corp.relations@bseindia.com

Re: Reporting of Outstanding Share Ownership

Dear Sir or Madam:

This letter is filed on behalf of OppenheimerFunds, Inc. ("OFI") and its clients for the purpose of reporting the ownership of shares of Glenmark Pharmaceuticals Ltd ("Company"). OFI is an investment adviser registered under the U.S. Investment Advisers Act of 1940 that provides investment advice to various mutual funds and other accounts ("OFI Clients"). The shares of the Company are held by OFI on behalf of various OFI Clients only for investment purposes. Neither OFI nor OFI Clients exercises or intends to exercise control over the company.

Pursuant to the regulations, the following information is provided with respect to OFI and its share ownership of the Company:

OFI holds all shares attributed to it solely in its capacity as investment adviser to OFI Clients. OFI generally has no economic interests (e.g., the right to dividends or proceeds from sale) in the Company's shares. OFI generally has the right to vote shares of portfolio companies held on behalf of OFI Clients.

Percentage Ownership: As of the close of business 4 October 2017, OFI had voting and/or dispositive power with respect to an aggregate of 8,488,000 shares of the Company's Common Stock on behalf of various OFI Clients. Our records indicate that OFI held 3.01% of

OppenheimerFunds, Inc.
225 Liberty Street
New York, NY10281-1008
Tel 800 225 5677
www.oppenheimerfunds.com


the outstanding shares of the Company on behalf of OFI Clients.
The above percentage was calculated based on our understanding
that the Company has 282,168,164 shares of Common Stock
outstanding.

Please find attached form as required by Regulation 29(2) of the Code. We trust that this notice
satisfies our requirements. Should you need any additional information, please do not hesitate to
contact Judith Gottlieb at jgottlieb@ofiglobal.com.

Kind regards,

6 October 2017

Date



Signature

Christina Carroll, VP Compliance

Name/Title

Annexure-B
Format for Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

| | | | |
|--|---------------------------------|---|--|
| 1. Name of the Target company (TC) | Glenmark Pharmaceuticals Ltd. | | |
| 2. Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer | OppenheimerFunds, Inc. (F.I.I.) | | |
| 3. Whether the acquirer belongs to Promoter/Promoter group | No | | |
| 4. Name(s) of the Stock Exchange(s) where the shares of TC are Listed | MCXX, XBOM, XNSE | | |
| 5. Details of the acquisition / disposal as follows | Number | % w.r.t. total share/voting capital wherever applicable (*) | % w.r.t. total diluted share/voting capital of the TC (**) |
| <u>Before the acquisition under consideration, holding of :</u> | | | |
| a) Shares carrying voting rights | 8,648,000 | 3.06% | 3.06% |
| b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others) | - | - | - |
| c) Voting rights (VR) otherwise than by equity shares | - | - | - |
| d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) | 0.00 | - | - |

| | | | |
|--|------------------|--------|--------|
| Total (a+b+c+d) | 8,648,000 | 3.06% | 3.06% |
| <u>Details of acquisition/sale</u> | | | |
| a) Shares carrying voting rights acquired/sold | -160,000 | -0.06% | -0.06% |
| b) VRs acquired/sold otherwise than by equity shares | - | - | - |
| c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold | - | - | - |
| d) Shares encumbered / invoked/released by the acquirer | - | - | - |
| Total (a+b+c+/-d) | -160,000 | -0.06% | -0.06% |
| <u>After the acquisition/sale, holding of:</u> | | | |
| a) Shares carrying voting rights | 8,488,000 | 3.01% | 3.01% |
| b) Shares encumbered with the acquirer | - | - | - |
| c) VRs otherwise than by equity shares | - | - | - |
| d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition | - | - | - |
| Total (a+b+c+d) | 8,488,000 | 3.01% | 3.01% |
| 6. Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc). | Open market | | |
| 7. Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is | October 04, 2017 | | |

| | |
|---|--|
| applicable. | |
| 8. Equity share capital/ total voting capital of the TC before the said acquisition / sale. | Rs. 282,168,164 (based on par value of Rs 1.00 and total issued shares of 282,168,164) |
| 9. Equity share capital/ total voting capital of the TC after the said acquisition / sale. | Rs. 282,168,164 (based total issued shares of 282,168,164) |
| 10. Total diluted share/ voting capital of the TC after the said acquisition. | 282,168,164 |

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.



 Signature of the acquirer / Authorized Signatory

For and on behalf of OppenheimerFunds, Inc.

Place : New York, New York

Date : October 06, 2017